1
Michael A Boss, John H Kenten, John S Emtage, Clive R Wood: Multichain polypeptides or proteins and processes for their production. Celltech, Cushman Darby & Cushman, March 28, 1989: US04816397 (816 worldwide citation)

Multichain polypeptides or proteins and processes for their production in cells of host organisms which have been transformed by recombinant DNA techniques. According to a first aspect of the present invention, there is provided a process for producing a heterologous multichain polypeptide or protei ...


2
Clive R Wood, Lori Jo Fitz: Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]. Genetics Institute, Steven R Lazar, December 21, 1999: US06004937 (48 worldwide citation)

Methods are provided for the modulation of the effects of GDF-8 and BMP-11, particularly on neural and muscular disorders administration of follistatin for treating neural, muscle, disorders which are characterized by an abnormality in the levels or activity of GDF-8 or BMP-11.


3
Mary Collins, Clive R Wood, Beatriz M Carreno, Deborah Luxenberg, Jason Jussif, Laura L Carter, Frances K Bennett, Vila Valge Archer, John Andrews, Caroline Russell: Antibodies against PD-1. Wyeth, MedImmune, Wolf Greenfield & Sacks P C, February 10, 2009: US07488802 (39 worldwide citation)

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for exampl ...


4
Mary Collins, Clive R Wood, Beatriz M Carreno, Deborah Luxenberg, Jason Jussif, Laura L Carter, Frances K Bennett, Viia Valge Archer, John Andrews, Caroline Russell: Methods of upmodulating adaptive immune response using anti-PD-1 antibodies. MedImmune, Wyeth, Wolf Greenfield & Sack P C, April 21, 2009: US07521051 (26 worldwide citation)

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for exampl ...


5
Gordon J Freeman, Irene Chernova, Tatyana Chernova, Nelly Malenkovich, Clive R Wood: Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1. Dana Farber Cancer Institute, Genetics Institute, Foley Hoag, May 4, 2010: US07709214 (21 worldwide citation)

The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, ...


6
Clive R Wood, Daniel T Dransfield, Henk Pieters, Rene Hoet, Simon E Hufton: Method of inhibition of vascular development using an antibody. Dyax, Lahive & Cockfield, Giulio A DeConti, Maria Laccotripe Zacharakis, February 3, 2009: US07485297 (14 worldwide citation)

Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity and angiogenesis. The ...


7
Mary Collins, Clive R Wood, Beatriz M Carreno, Deborah Luxenberg, Jason Jussif, Laura L Carter, Frances K Bennett, Viia Valge Archer, John Andrews, Caroline Russell: Nucleic acids encoding antibodies against PD-1. Wyeth, MedImmune, Wolf Greenfield & Sacks P C, January 3, 2012: US08088905 (8 worldwide citation)

This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for exampl ...


8
Clive R Wood, Gordon J Freeman: Methods of upmodulating an immune response with non-activating forms of B7-4. Dana Farber Cancer Institute, Genetics Institute, Foley Hoag, December 29, 2009: US07638492 (7 worldwide citation)

The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory ...


9
Clive R Wood, Daniel T Dransfield, Henk Pieters, Rene Hoet, Simon E Hufton: Antibodies to Tie1 ectodomain. Dyax, McCarter & English, Maria Laccotripe Zacharakis, Marcie B Clarke, January 18, 2011: US07871610 (6 worldwide citation)

Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity.


10
Laetitia Devy, Henk Pieters, Robert C Ladner, Rene Hoet, Daniel T Dransfield, Clive R Wood, Maria Henderikx: Antibodies that bind MMP-14. Dyax, Lando & Anastasi, June 29, 2010: US07745587 (6 worldwide citation)

Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.